AzTrials
AzTrials

Dry Eye DiseasePhase 1NCT05031806

Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease

A Phase 1 study testing iNexin™ (0.08% aCT1), iNexin™ (0.4% aCT1) and iNexin™ (2.0% aCT1) in people with Dry Eye Disease, run by Xequel Bio, Inc. at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective of this study is to evaluate the safety and tolerability of iNexin™ The secondary objective is to compare the efficacy of iNexin™ to Vehicle for the treatment of the signs and symptoms associated with dry eye disease. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Dry Eye Disease
What is being tested?
iNexin™ (0.08% aCT1), iNexin™ (0.4% aCT1) and iNexin™ (2.0% aCT1)
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
30 participants
Where
1 siteUnited States
Study dates
28 Sep 2021to 1 Dec 2021
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects must meet all the following requirements to be eligible for enrollment into the study.
  • Be at least 18 years of age;
  • Provide written informed consent;
  • Have a self-reported history of dry eye for at least 6 months prior to Visit 1;
  • Have a history of use or desire to use eye drops for dry eye symptoms for at least 6 months prior to Visit 1;
  • Report a score of ≥ 2 according to a 0-5 point scale in at least one symptom of the Ora Calibra Ocular Discomfort \& 4-Symptom Questionnaire pre-CAE at Visits 1 and 2;
Show all 16Show fewer
  • Have a conjunctival redness score of ≥ 1 according to a 0-4 point scale in at least one eye at Visits 1 and 2;
  • Have a tear film break-up time (TFBUT) >1 and < 7 seconds in at least one eye pre-CAE at Visit 1 and 2;
  • Have an unanesthetized Schirmer's Test score of ≤ 10 mm and ≥ 1 mm in at least one eye pre-CAE at Visits 1 and 2;
  • Have a corneal fluorescein staining sum of ≥ 6 according to a 0-4 point scale (sum of inferior, superior, and central) in at least one eye pre-CAE at Visits 1 and 2;
  • Have a central corneal fluorescein staining score of ≥ 1 according to a 0-4 point in at least one eye pre-CAE at Visits 1 and 2;
  • Have a total lissamine green conjunctival score of ≥ 2, based on the sum of the temporal and nasal regions of the conjunctiva according to a 0-4 point scale in at least one eye pre-CAE at Visits 1 and 2;
  • Demonstrate a response to the CAE at Visits 1 and 2 as defined by:
  • Having at least a ≥ 1 point increase in fluorescein staining in the inferior region in at least one eye following CAE exposure; and
  • Reporting an Ocular Discomfort score ≥ 3 at 2 or more consecutive time points in at least one eye during CAE exposure (if a subject has an Ocular Discomfort rating of 3 at time = 0 for an eye, s/he must report an Ocular Discomfort rating of 4 for two consecutive measurements for that eye).
  • Have at least one eye (the same eye) satisfy all criteria for 6, 7, 8, 9, 10, 11, and 12 above.

Who cannot join

  • Subjects may not participate in the study if any of the following criteria are met:
  • Unable or unwilling to follow instructions, including participation in all study assessments and visits;
  • Have active blepharitis, meibomian gland dysfunction (MGD) or lid margin inflammation that required any topical or systemic antibiotics or topical steroids or other prescription medical treatment or treatment with hypochlorous acid wipes within the last 3 months prior to Visit 1 or will require such treatment during the trial.
  • Any other therapy such as lid scrubs, lid wipes, warm compresses have to be stable within the last 3 months prior to Visit 1 and the subject should be willing to continue those therapies through the trial
  • Have active ocular allergies that require therapeutic treatment, and/or in the opinion of the Investigator may interfere with study parameters;
  • Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;
Show all 34Show fewer
  • Have a significant ocular lesion that the investigator feels might affect ocular surface staining score;
  • Have worn contact lenses within 14 days of Visit 1 or anticipate using contact lenses during the study;
  • Have previously had laser-assisted in situ keratomileusis (LASIK) or any other Laser refractive surgery within the last 12 months or any other ocular surgeries within the last 6 months;
  • Have any planned ocular and/or lid surgeries over the study period;
  • Current smoker (includes tobacco, marijuana, or vaping) or has smoked within 6 months of Visit 1;
  • Has dry eye secondary to known systemic diseases or comorbidities:
  • Previous diagnosis of graft versus host disease or cicatrizing conjunctivitis (e.g., Steven-Johnson Syndrome, mucous membrane pemphigoid, trachoma, trauma);
  • Anatomical or neurological lid closure problems (e.g., Bell's palsy, cicatricial ectropion, Alzheimer's disease, Parkinson's disease);
  • Has dry eye secondary to other ocular surface diseases or ocular surgery:
  • Ocular rosacea, blepharitis, demodex infestation, atopic keratoconjunctivitis, etc.;
  • Any history of surgery for glaucoma (e.g., trabeculectomy, tube shunt);
  • Cataract, eyelid surgery, or retinal surgery (in operating room) within 6 months prior to enrollment;
  • Any in-office dry eye procedures (e.g., Intense Pulsed Light [IPL], LipiFlow , nasolacrimal duct probing) within 90 days prior to enrollment;
  • Has a history of corneal dystrophy that in the opinion of the investigator is significantly affecting the ocular surface (e.g., significant anterior basement membrane dystrophy, Fuch's dystrophy with significant corneal edema and bullae, neurotrophic keratoconjunctivitis or corneal/conjunctival scarring including herpes simplex virus [HSV] or varicella zoster virus [VZV] keratitis);
  • Has any physical or mental condition interfering with the successful participation in this study;
  • Has had any past head and neck radiation treatment;
  • Be using or anticipate using temporary punctal plugs;
  • Be using or anticipate using permanent punctal plugs during the study that have not been stable within 3 months of Visit 1;
  • Have had punctal occlusion (other than permanent punctal plugs) within 6 months of Visit 1;
  • Have corrected visual acuity greater than or equal to logMAR+0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in either eye at Visit 1
  • Have an uncontrolled systemic disease;
  • Be a woman who is pregnant, nursing or planning a pregnancy;
  • Be unwilling to submit a urine pregnancy test at Visit 1 and Visit 5 (or early termination visit) if a woman of childbearing potential (WOCBP). Non-childbearing potential is defined as a woman who is permanently sterilized (e.g. has had a hysterectomy or tubal ligation), or is post-menopausal (without menses for 12 consecutive months);
  • Be a woman of childbearing potential (WOCBP) who does not have a negative pregnancy test at Screening or who does not agree to use an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; surgical sterilization of partner; For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use adequate birth control as defined above for the remainder of the study. Male subjects must abstain from sex with WOCBP or use an adequate method of contraception (as described above) from the time of informed consent through the end of the study;
  • Have a known allergy and/or sensitivity to the test article or its components;
  • Have a condition or be in a situation which the Investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study;
  • Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days of Visit 1;
  • Have used any of the following treatments in the period indicated before Visit 1 or anticipate their use at any time during the study: Day of Visit 1 1. All topical ophthalmic preparations (e.g., over-the counter-solutions, artificial tears, gels, scrubs, ointments) 7 days prior to Visit 1 2. Antihistamines (including topical ophthalmic antihistamines) 3. Medications for glaucoma 30 days prior to Visit 1 4. Topical ophthalmic non-steroidal anti-inflammatories 5. Topical ophthalmic corticosteroids 6. Topical ophthalmic autologous serum 7. Topical ophthalmic antibiotics 8. Mast cell stabilizers (Zaditor and Alamast ) 9. Oral aspirin or aspirin-containing products except in the case that it was taken on a stable daily dosing regimen for at least 30 days prior to Visit 1 and is expected to be taken on the same regimen throughout the study period 10. Any other medication known to cause ocular drying (e.g., anticholinergics, diuretics, antidepressants, beta blockers) except in the case that it was taken on a stable daily dosing regimen for at least 30 days prior to Visit 1 and is expected to be taken on the same regimen throughout the study period 12 weeks prior to Visit 1 11. Restasis 12. Xiidra 13. CEQUA™ 14. Eysuvis™ 15. LipiFlow or other similar meibomian gland dysfunction (MGD) therapy 16. TrueTear 17. Corticosteroids (e.g., systemic steroids including intravenous, intramuscular, intraarticular, and oral steroids; facial topical steroids; dermatological steroids with high potency or large treatment areas); 18. Tetracyclines (tetracycline, doxycycline, minocycline, etc.)

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Andover Eye Associates

    Andover, Massachusetts, 01810

Other trials in United States

About this study

Official title: A Single-Center, Randomized, Double Masked, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of iNexin™ Eye Drops Compared to Vehicle in Subjects With Dry Eye Disease

The primary objective of this study is to evaluate the safety and tolerability of iNexin™ The secondary objective is to compare the efficacy of iNexin™ to Vehicle for the treatment of the signs and symptoms associated with dry eye disease.

Read the detailed description

The clinical hypothesis for this study is that iNexin™ demonstrates safety and tolerability in subjects with DED and can be evaluated for further safety and efficacy measures compared to vehicle. This is a Phase 1b single-center, randomized, double masked, vehicle controlled clinical study to assess the safety and exploratory efficacy of iNexin™ compared to vehicle in subjects with Dry Eye Disease. A total of 36 subjects, at least 18 years of age, with a subject-reported history of DED in both eyes and meeting all other study eligibility criteria will be randomized to receive treatment with iNexin™ or vehicle.

An individual subject's participation time is expected to be approximately 24 days. 36 eligible subjects will be randomized in a 2:1 allocation for each of three concentrations of iNexin™ to Vehicle, to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). There will also be a 1-day post-final dose follow-up visit (Visit 5).

During a 7-day study run-in period prior to randomization (from Visit 1 to the evening before Visit 2), all subjects will receive Vehicle eye drops (Vehicle) bilaterally at the same dosing frequency as iNexin™ (BID).

Conditions
Dry Eye Disease
Being tested
iNexin™ (0.08% aCT1), iNexin™ (0.4% aCT1), iNexin™ (2.0% aCT1), Vehicle (eye drop formulation without aCT1)
Medical subject headings
Dry Eye Syndromes

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • iNexin™ (0.08% aCT1)Drug

    36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.randomized 7:3 for each active concentration to Vehicle.

  • iNexin™ (0.4% aCT1)Drug

    36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.

  • iNexin™ (2.0% aCT1)Drug

    36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.

  • Vehicle (eye drop formulation without aCT1)Drug

    36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.

    During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).

Study groups in NCT05031806
Study groupRoleWhat they receive
iNexin™ (0.08% aCT1)Experimental36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
Receives: Drug: iNexin™ (0.08% aCT1)
iNexin™ (0.4% aCT1)Experimental36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
Receives: Drug: iNexin™ (0.4% aCT1)
iNexin™ (2.0% aCT1)Experimental36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
Receives: Drug: iNexin™ (2.0% aCT1)
Vehicle (eye drop formulation without aCT1)Placebo comparator36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
Receives: Drug: Vehicle (eye drop formulation without aCT1)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluation of the safety of iNexin™

    Assessed using: Visual Acuity (VA) (ETDRS), Slit-lamp biomicroscopy, Adverse Event Query, Dilated Fundoscopy Interocular Pressure

    Measured: Through study completion, an average of 24 days

  2. Evaluation of the tolerability of iNexin™

    Assessed using: Ora Calibra Drop Comfort Assessments

    Measured: Through study completion, an average of 24 days

Secondary outcomes (1)

  1. Comparison of the efficacy of iNexin™ to Vehicle for the treatment of the signs and symptoms associated with dry eye disease

    Efficacy measures: Corneal fluorescein staining using the Ora Calibra Corneal and Conjunctival Staining Scale, Conjunctival lissamine green staining using the Ora Calibra Corneal and Conjunctival Staining Scale, Visual Analogue Scale (VAS) for symptoms, Tear film break-up time (TFBUT), Ora Calibra Conjunctival Redness, Unanesthetized Schirmer's Test, Ora Calibra Ocular Discomfort Scale, Ora Calibra Ocular Discomfort \& 4- Symptom Questionnaire; OSDI

    Measured: Through study completion, an average of 24 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Sep 2021
  2. Study start28 Sep 2021
  3. Primary completion1 Dec 2021
  4. Study completion1 Dec 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05031806
Sponsor's protocol ID
2021-OCLR-01b
Other IDs
CDMRP-VR190131
Status last verified
Mar 2022
First submitted
17 Aug 2021
Last updated
4 Mar 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing iNexin™ (0.08% aCT1), iNexin™ (0.4% aCT1) and iNexin™ (2.0% aCT1) in people with Dry Eye Disease, run by Xequel Bio, Inc. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 16 inclusion and 34 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluation of the safety of iNexin™ (time frame: Through study completion, an average of 24 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05031806.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2022.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in